ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2022

MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients.

Xiaoman Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.